Oral pill for relapsing multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests an experimental oral drug, PRO-1562, in two parts: first in healthy volunteers to check safety, then in people with relapsing multiple sclerosis to see if it can reduce disease activity. It may offer a new, convenient treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older (implied) and weigh at least 105.6 pounds.
- Your body mass index (BMI) must be between 18.5 and 30.
- You must be in good general health with no significant medical conditions.
- You must be willing to use highly effective contraception for at least 30 days after the study ends.
- You cannot have received certain vaccines (mRNA or live) in the last 60 days, and no other investigational drugs in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental oral drug called VT7208 in both healthy volunteers and people with multiple sclerosis (MS). The goal is to see if it is safe and how the body processes it, which could lead to a new treatment option for MS.
This study tests whether an mRNA vaccine (mRNA-1195) can help prevent relapses in people with early relapsing multiple sclerosis (MS). It compares the vaccine to a placebo (a shot with no active ingredient) to see if it is safe and effective.
This study tests whether adding a probiotic supplement to your usual MS treatment (or to no treatment) can help manage relapsing-remitting multiple sclerosis. It aims to see if the probiotic is safe and beneficial as an add-on therapy.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This trial tests whether cladribine (vs an inactive placebo pill) can slow disability worsening in people with a non-active, progressive form of multiple sclerosis. It may help by reducing the immune activity that can drive ongoing nerve damage, even without recent relapses.
This study tests a new medicine given as a shot under the skin for people with relapsing multiple sclerosis. It aims to see if the medicine is safe and how well it works in reducing MS activity.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.